Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations
Executive Summary
Glaxo Wellcome's withdrawal of Lotronex suggests that hurdles remain in FDA's efforts to expand the use of risk management programs for approved products.
You may also be interested in...
Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies
Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies
Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”
Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy